{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:37:42Z","timestamp":1770831462934,"version":"3.50.1"},"reference-count":0,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,11,14]],"date-time":"2003-11-14T00:00:00Z","timestamp":1068768000000},"content-version":"vor","delay-in-days":2508,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[1997,1]]},"abstract":"<jats:p>Abstract. Increased plasma Lp(a) is an established risk factor for atherosclerosis. We recently described the presence of apo(a) fragments in urine and the significant correlation between urinary apo(a) concentrations and plasma Lp(a). Here we investigated urinary apo(a) in patients suffering from familial hypercholesterolaemia (FH), treated with LDL apheresis. Before treatment, plasma Lp(a) levels and urinary apo(a) normalized to creatinine were &gt;2\u2010fold increased in FH patients (<jats:italic>P<\/jats:italic>\u2003&lt;0.0001) as compared to controls. LDL\u2010apheresis led to a reduction of plasma Lp(a) by 75% and a concommittant immediate reduction of urinary apo(a) by 45%. We conclude that a steady state condition for urinary apo(a) is rapidly achieved via LDL\u2010apheresis.<\/jats:p>","DOI":"10.1046\/j.1365-2362.1997.00108.x","type":"journal-article","created":{"date-parts":[[2003,11,14]],"date-time":"2003-11-14T14:19:43Z","timestamp":1068819583000},"page":"93-95","source":"Crossref","is-referenced-by-count":15,"title":["<b>LDL\u2010apheresis significantly reduces urinary apo(a) excretion<\/b>"],"prefix":"10.1111","volume":"27","author":[{"given":"K. M.","family":"KOSTNER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"JANSEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"MAURER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"DERFLER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,11,14]]},"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2362.1997.00108.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2362.1997.00108.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T19:45:55Z","timestamp":1698435955000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2362.1997.00108.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,1]]}},"alternative-id":["10.1046\/j.1365-2362.1997.00108.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2362.1997.00108.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,1]]}}}